Novel Compounds with Potent Anti-Tumor Activity (Case 2071)

Principal Investigators:

 

Richard Moore, MD, Professor

Rakesh Singh, PhD, Assistant Professor

 

Department of Bio Med Obstetrics - Gynecology

Brown University

Providence, RI

 

Brief Description:

 

The latest National Cancer Institute report indicates that the incidence rate of almost all cancer types is on the rise. Spending on cancer treatment is rising in the same fashion. At the present time, Isothiocyanates (ITC’s) are being studied for their potent chemo preventative potential against chemically induced cancers. ITC’s are a small family of organic compound that occur in wide variety of plants, many of which are consumed by humans on regular basis. Many studies have shown that ITC’s inhibit cancer growth by inducing apoptosis. Recent epidemiological studies suggest that humans who consumed higher levels of ITC’s might be less likely to develop lung and colon cancer. ITC’s are rapidly metabolized in both humans and animals and give rise to various derivatives. The anti-carcinogenic potential of ITC’s is demonstrated further by the finding that these metabolites possess similar, if not more potent, anti-carcinogenic activity in cultured cells or animal models. It has been discovered that the derivatives of one ITC in particular, adamantyl (AM-ITC), display anticancer activity.

 

The technology includes the methods of administration and the compositional formula for four adamantyl derivative compounds that have demonstrated anti-carcinogenic properties in vitro in various cultured solid tumor cancer cells such as neuroblastoma, breast, ovarian, endometrial, prostate, pancreatic, vulvar, liver and in other non-solid human tumors as well. A therapeutically or pharmaceutically effective amount of adamantyl derivatives can be administered to a patient to treat or prevent neoplastic disease with particular reference to cancer. The derivatives also have applications in the treatment of patients infected with HIV.

                           

Information:

 

US patent 8,772,335 is issued (07/08/2014)

US patent 9,168,237 is issued (10/27/2015)

Chem Biol Drug Des 2012; 79:92-103

Patent Information:
Category(s):
Oncology
For Information, Contact:
Margaret Shabashevich,
Manager of Operations
Technology Ventures Office
Brown University
401-863-7499 TVO_Patents@brown.edu
Inventors:
Richard Moore
Rakesh Singh
Keywords:
© 2017. All Rights Reserved. Powered by Inteum